These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30131256)

  • 1. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
    Probstfield JL; Boden WE; Anderson T; Branch K; Kashyap M; Fleg JL; Desvigne-Nickens P; McBride R; McGovern M;
    J Clin Lipidol; 2018; 12(6):1413-1419. PubMed ID: 30131256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial.
    Toth PP; Jones SR; Slee A; Fleg J; Marcovina SM; Lacy M; McBride R; Boden WE
    J Clin Lipidol; 2018; 12(3):741-747.e11. PubMed ID: 29627296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
    J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
    J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
    Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
    Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
    Teo KK; Goldstein LB; Chaitman BR; Grant S; Weintraub WS; Anderson DC; Sila CA; Cruz-Flores S; Padley RJ; Kostuk WJ; Boden WE;
    Stroke; 2013 Oct; 44(10):2688-93. PubMed ID: 23881958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial.
    Lyubarova R; Robinson JG; Miller M; Simmons DL; Xu P; Abramson BL; Elam MB; Brown TM; McBride R; Fleg JL; Desvigne-Nickens P; Ayenew W; Boden WE;
    J Clin Lipidol; 2017; 11(5):1201-1211. PubMed ID: 28807460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
    Boden WE; Miller MG; McBride R; Harvey C; Snabes MC; Schmidt J; McGovern ME; Fleg JL; Desvigne-Nickens P; Anderson T; Kashyap M; Probstfield JL
    Am Heart J; 2020 Jun; 224():65-76. PubMed ID: 32335402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
    Kalil RS; Wang JH; de Boer IH; Mathew RO; Ix JH; Asif A; Shi X; Boden WE
    Kidney Int; 2015 Jun; 87(6):1250-7. PubMed ID: 25651367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3.
    Taylor AJ; Lee HJ; Sullenberger LE
    Curr Med Res Opin; 2006 Nov; 22(11):2243-50. PubMed ID: 17076985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study.
    Liu J; Wang W; Wang M; Sun J; Liu J; Li Y; Qi Y; Wu Z; Zhao D
    Diabetes Res Clin Pract; 2012 May; 96(2):217-24. PubMed ID: 22244364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.